To demonstrate independent prognostic implications of POLE expression, we performed subgroup survival analysis, including analyses of clinicopathological characteristics and abundance of immune cells in 533 patients with ccRCC in TCGA data. The gene discussed is POLE; the disease is nonpapillary renal cell carcinoma.